# A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Source: https://onco.cc/trials/nct04104776/  
OnCo record `nct04104776` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Enzalutamide in diffuse large b-cell lymphoma and mesothelioma, run by Novartis Pharmaceuticals, now recruiting.

## Summary

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas is a phase 1/2 interventional study registered as NCT04104776 by Novartis Pharmaceuticals, with 300 participants planned, started 2019-09-18 and due to reach its primary completion in 2030-02-27. Interventions recorded: Tulmimetostat, Enzalutamide. Conditions listed: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04104776
- Phase: 1/2
- Setting: A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT04104776: https://clinicaltrials.gov/study/NCT04104776

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Enzalutamide](https://onco.cc/drugs/enzalutamide/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/nct04104776.json